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INTRODUCTION
Epithelial ovarian cancer (OCa) affects nearly 25000 women in 
North America every year and is the fifth most common malig-
nancy in women with a five-year mortality of over 70%.1 Be-
cause the symptoms are often not observed until the cancer 
has spread extensively, less than 25% of women are diagnosed 
at early stage of the disease. Combined surgery and cytotoxic 
therapy produce favorable clinical responses in 50% to 80% of 
patients; however, the majority of patients relapse. Therefore, it 
is crucial to search for new biologically targeted treatment mo-
dalities.2,3
The Müllerian duct, which is formed from the coelomic epi-
thelium, develops into the Fallopian tubes, uterus, cervix, prox-
imal vagina, and the surface epithelium of the ovaries in fe-
males.4 Müllerian inhibiting substance (MIS), also referred to 
as anti-Müllerian hormone or AMH, is a glycoprotein composed 
of two identical 535 amino acid residues subunits with a com-
bined molecular weight of 140 kDa. MIS belongs to the trans-
forming growth factor-β (TGF-β) family along with bone mor-
phogenetic protein, activin, and inhibin.5 Several studies have 
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Effect of MIS and Calcitriol on Ovarian Cancer
suggested that MIS inhibits the growth of cell lines and tissues 
of MIS receptor-expressing gynecological malignancies such 
as breast, endometrial, cervical, and ovarian cancer.6-10
Calcitriol (1, 25-dihydroxycholecalciferol), the hormonally 
active form of Vitamin D (Vit D), has long been known as an 
important regulator of calcium homeostasis and bone metab-
olism through its activity in the intestines, bones, kidneys, and 
the parathyroid glands.11 Emerging evidence indicates that 
calcitriol may be implicated in the regulation of other impor-
tant biological processes such as insulin secretion, immune 
response, pro-differentiation, anti-proliferation, pro-apopto-
sis, anti-angiogenesis, inhibition of invasion and metastasis, 
and antiinflammation.12 It has recently been suggested that 
MIS constitutes a novel target regulated by calcitriol in prostate 
cells, and that induction of MIS expression may play an impor-
tant role in the anti-cancer activity of calcitriol.13,14
Growing evidence suggesting that MIS and calcitriol can act 
synergistically to inhibit the growth of tumor cells prompted us 
to examine the effects of MIS in combination with calcitriol on 
OCa cell lines. Therefore, the purpose of this study was to inves-
tigate whether MIS in combination with calcitriol modulates 
the proliferation and apoptosis of human OCa cell lines 
(SKOV3, OVCAR3, and OVCA433) and to identify the signaling 
pathway by which MIS and calcitriol mediate proliferation and 
apoptosis.
MATERIALS AND METHODS
Cell culturing
Human epithelial OCa cell lines (SKOV3, OVCAR3, and OVCA 
433) were cultured in RPMI-1640 medium (Gibco-BRL, Gaith-
ersburg, MD, USA) supplemented with 10% fetal bovine serum 
(FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin. The 
cells were incubated in a humidified atmosphere containing 
5% CO2 at 37°C. 
MIS type II receptor (MISRII) detection
MIS type II receptor (MISRII) expression was examined in 
SKOV3, OVCAR3, and OVCA433 cell lines by western blot anal-
ysis, performed with rabbit polyclonal antihuman MISRII anti-
serum (Abcam, Cambridge, MA, USA).
Cell viability and proliferation assay
Cell viability and proliferation were measured using the Cell 
Counting Kit-8 (CCK-8) assay (Dojindo Laboratories, Kuma-
moto, Japan). Cells were seeded in a 96-well flat-bottomed 
plate (2×103 cells in 100 μL per well), incubated overnight to al-
low for cell attachment and recovery, and then exposed to MIS 
(USCN Life Science Inc., Wuhan, Hubei, China) and calcitriol 
(Sigma, St. Louis, MO, USA) dissolved in methanol for 24, 48, 
72, and 96 h. Next, CCK-8 solution (10 μL) was added to each 
well, and the cells were incubated for an additional two hours. 
Absorbance at 450 nm was measured with a microplate reader. 
Treatment of cells with inhibitors
Cells were seeded at a density of 5×103 cells/100-mm dish. Fol-
lowing the 48-h incubation, they were washed with a serum-
free medium and then transferred into media without FBS at 
least 16 h prior to the start of the experiments. Cells were pre-
treated with 20 μM each of the following inhibitors: SB203580 
(Sigma), a p38 mitogen-activated protein kinase (p38 MAPK) 
inhibitor; PD98059 (Sigma), an extracellular signal-regulated 
kinase (ERK) inhibitor; LY294002, a phosphoinositide 3-kinase 
(PI3K) inhibitor; and SP600125 (Sigma), a c-Jun amino-termi-
nal kinase (JNK) inhibitor.
Western blot analysis
Following treatment, cells were collected and centrifuged and 
whole-cell lysates were prepared using a lysis buffer. Total pro-
tein concentration was determined using a DC protein assay 
kit (Bio-Rad, Hercules, CA, USA). Thirty micrograms of pro-
tein was directly separated by 10% SDS-polyacrylamide gel 
electrophoresis (PAGE) and transferred to polyvinylidene diflu-
oride (PVDF, Bio-Rad Laboratories). Blocked membranes were 
Fig. 1. Effects of MIS and calcitriol on the viability of ovarian cancer (OCa) cells. (A) Cells were treated with a range of MIS (35.5–284 nM) to determine 
the IC50 for each cell line. (B) Cells were treated with a range of calcitriol concentrations (1–100 µM) to determine the IC50 for each cell line. Values are 
presented as a percentage of the control and were calculated using the following equation: [(mean absorbance of treated cells)/(mean absorbance 
of control cells)]×100. Data are expressed as mean±SD from three independent experiments. For all subsequent experiments, MIS and calcitriol 
concentrations were held constant at or near their IC50, 71 nM and 50 μM, respectively. MIS, Müllerian inhibiting substance.
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Fig. 2. Viability and proliferation assays conducted with ovarian cancer (OCa) cell lines treated with MIS and calcitriol (relative cell growth as a function of 
time). MIS and calcitriol concentrations were held constant at or near their IC50; 71 nM MIS and 50 μM calcitriol. Cells were treated with vehicles (control), 
71 nM MIS (MIS), 50 μM calcitriol (calcitriol), or both agents (MIS+calcitriol). Combined use of calcitriol and MIS reduces cell proliferation of human OCa 
cell lines (SKOV3, OVCAR3, and OVCA433). Cell growth was monitored for 96 h post treatment. For the combination treatment, cells were pretreated with 
calcitriol (50 μM) for 4 h prior to the addition of MIS (71 nM). Cell proliferation was measured using the Cell Counting Kit-8 solution as described in the Ma-
terials. Results are representative of three experiments. Data in the bar graph represent mean±SD. *p<0.05 vs. control, †p<0.05 vs. MIS. MIS, Müllerian 
inhibiting substance.
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then incubated with primary antibodies overnight at 4°C. B-
cell lymphoma 2 (Bcl-2), Bcl-2 associated X protein (BAX), 
ERK, phospho-ERK, JNK, and phosphor-JNK purchased from 
Cell signaling Technology (Beverly, MA, USA); and caspase-3 
and caspase-9 from Biovision (Milpitas, CA, USA) were used 
at a 1:1000 dilution. Subsequent to washing, the membranes 
were incubated with a horseradish peroxidase-conjugated an-
ti-rabbit or anti-mouse secondary antibody (Santa Cruz, Bio-
technology, Santa Cruz, CA, USA). The blots were re-probed 
with anti-β-actin antibody as a loading control. Protein bands 
Fig. 3. Calcitriol enhances MIS-induced apoptosis in OCa cell lines. Cells (1×105/well) were pretreated with or without calcitriol (50 μM) for 4 h prior to 
the addition of MIS (71 nM). Apoptosis was measured as cellular DNA fragmentation determined by ELISA. Results are representative of three exper-
iments. Significant inhibition relative to the control (MIS 0 nM) is indicated by an asterisk and the cross indicates a significant difference relative to 
the MIS treatment (MIS 71 nM). Data are presented as mean±SD. *p<0.05 vs. control, †p<0.05 vs. MIS. MIS, Müllerian inhibiting substance; ELISA, 
enzyme-linked immunosorbent assay; OD, optical density.
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Fig. 4. MIS and calcitriol alter the expression of regulatory proteins in SKOV3. Cells were treated with vehicles (control), 71 nM MIS (MIS), 50 μM cal-
citriol (calcitriol), or both (MIS+calcitriol). For the combined treatment, cells were incubated in the presence or absence of calcitriol (50 μM) for 4 h 
followed by stimulation with MIS (71 nM) for 48 h. (A) Western blot analysis of caspase-9 and caspase-3. (B) Western blot analysis of Bcl-2 and BAX. 
Band intensities were quantitated and data are presented as mean±SD. *p<0.05 vs. control, †p<0.05 vs. MIS. MIS, Müllerian inhibiting substance; Bcl-
2, B-cell lymphoma 2; BAX, Bcl-2 associated X protein.
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were visualized using an enhanced chemiluminescence sys-
tem (ECLTM; Amersham, Little Chalfont, UK) and band inten-
sities were quantified using the Luminescent image analyzer 
(LAS 4000 mini; Fujifilm, Uppsala, Sweden). All experiments 
were independently repeated three times.
DNA fragmentation assay
The DNA fragmentation assay was performed using enzyme-
linked immunosorbent assay (ELISA) with a DNA fragmenta-
tion Kit (Roche Applied Science, Indianapolis, IN, USA). Cells 
were seeded at a density of 1×105 cells per well in 96-well plates. 
Subsequent to 24 h growth, the medium was changed to a se-
rum-free one, and cells were grown for an additional 24 h. In 
order to label the DNA, the medium was replaced with 10% 
FBS-Dulbecco’s modified Eagle medium, 10 μM 5-bromo-2’-
deoxyuridine was added to each well, and cells were incubat-
ed for 24 h. Cells were treated with calcitriol for 4 h and then 
incubated with MIS for an additional 96 h. Cells were then lysed 
in 200 μL of incubation buffer, and soluble DNA fragments 
were quantified using the Cellular DNA fragmentation ELISA 
kit according to the manufacturer’s instructions. All experi-
ments were performed in triplicate.
Statistical analysis
Data were analyzed by Student’s t-test or ANOVA for each of 
the repeated experiments. For all analyses, statistically signifi-
cant differences were designated as p<0.05. Results are shown 
as mean±SD.
RESULTS
MISRII is expressed in ovarian cancer cell lines
Before evaluating the response of OCa cells to MIS, we first de-
termined whether the cells expressed MISRII. Thus, expression 
of MISRII was examined in SKOV3, OVCAR3, and OVCA433 
cell lines by western blot analysis, using a rabbit polyclonal an-
tihuman MISRII antiserum. All cell lines showed specific stain-
ing for MISRII, although expression in OVCAR3 was higher 
than in SKOV3 and OVCA433 (data not shown).
Growth inhibitory concentrations for MIS and calcitriol
OCa cells were treated with a range of MIS (35.5–284 nM) and 
calcitriol concentrations (1–100 μM) to determine the IC50 for 
each cell line. For all subsequent experiments, MIS and cal-
citriol concentrations were held constant at or near their IC50, 
71 nM and 50 μM, respectively (Fig. 1).
Cooperative effects of MIS and calcitriol on suppres-
sion of ovarian cancer cell proliferation 
SKOV3, OVCAR3, and OVCA433 cells were grown in plates for 
48 h, and then treated with 71 nM MIS and 50 μM calcitriol. 
After 24, 48, 72, and 96 h of treatment, the cells were incubated 
with CCK-8 solution and absorbance was read at 450 nm. As 
shown in Fig. 2, cell proliferation decreased significantly fol-
lowing 72 h of exposure to MIS combined with calcitriol.
Calcitriol enhanced MIS-induced apoptosis in ovarian 
cancer cell lines
The degree of apoptosis was analyzed by measuring the level 
of cellular DNA fragmentation using ELISA. A significant in-
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Fig. 5. Calcitriol increases MIS-induced ERK phosphorylation in SKOV3 cells. (A) Western blot analysis of ERK and phosphorylated ERK levels in SKOV3 
cells treated with MIS. Bands were detected with anti-ERK and anti phospho-ERK antibodies. (B) SKOV3 cells were treated with 71 nM MIS, 20 μM 
PD98059, or both for 2 h and the degree of apoptosis was analyzed by ELISA measuring the level of cellular DNA fragmentation. Significant increase 
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nM). (C) SKOV3 cells were incubated with or without calcitriol (50 μM) for 4 h prior to the addition of MIS (71 nM). Subsequent to 48 h of incubation, cells 
were harvested and ERK activation was analyzed by western blot analysis using anti-phospho-ERK antibody. *p<0.05 vs. control, †p<0.05 vs. MIS. MIS, 
Müllerian inhibiting substance; ERK, extracellular signal-regulated kinase; ELISA, enzyme-linked immunosorbent assay; OD, optical density.
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crease in DNA fragmentation was apparent in cells treated 
with MIS (71 nM) combined with calcitriol (50 μM), compared 
with the control. In addition, the results for the combination 
treatment were significantly different from MIS alone treat-
ment in all cell lines (Fig. 3). 
MIS and calcitriol alter the expression of regulatory 
proteins in SKOV3
To demonstrate that MIS and calcitriol-reduced cell prolifera-
tion was due to apoptotic activity, the levels of Bcl-2, BAX, cas-
pase-3, and caspase-9 were examined. SKOV3 cells were pre-
treated with or without calcitriol (50 μM) for 4 h prior to the 
addition of MIS (71 nM). Following 48 h of incubation, cells 
were analyzed by western blot analysis with anti-caspase-9 an-
tibody and anti-caspase-3 antibody; the expression of the 
apoptosis-related proteins Bcl-2 and BAX were also evaluated. 
Treatment of SKOV3 with MIS plus calcitriol induced apopto-
sis, as evidenced by an increase in the levels of BAX, caspase-3, 
and caspase-9 and a decrease in the levels of Bcl-2 (Fig. 4).
The effects of MIS plus calcitriol on the phosphorylation 
of ERK in SKOV3
Potential molecular mechanisms underlying the synergistic 
effect of calcitriol and MIS were assessed by western blot anal-
ysis following treatment with chemical inhibitors; p38 MAPK 
activation was inhibited with 20 μM SB203580, PI3K was in-
hibited with 20 μM LY294002, ERK was inhibited with 20 μM 
PD98059, and JNK signaling was inhibited with 20 μM 
SP600125. Although MIS did not activate the p38 MAPK, PI3K, 
or JNK pathway (data not shown), Fig. 5A indicates that the 
ERK pathway is activated by MIS. SKOV3 cells were then treat-
ed with 71 nM MIS, 20 μM PD98059, or both for 2 h and then 
the degree of apoptosis was analyzed by measuring the level 
of cellular DNA fragmentation using ELISA. A significant in-
crease in fragmentation was observed for the MIS treatment 
vs. the control (p<0.05) and MIS vs. PD98059 (p<0.05) (Fig. 
5B). Next, cells were incubated with or without calcitriol (50 
μM) for 4 h prior to the addition of MIS (71 nM). Following 48 
h of incubation, cells were harvested and ERK activation was 
analyzed by western blotting using an anti-phospho-ERK an-
tibody. The combination treatment resulted in the most in-
tense specific band compared to control, MIS alone, and cal-
citriol alone (Fig. 5C). 
DISCUSSION
The clinical use of cytotoxic drugs has had a significant impact 
on neoplastic diseases. However, their therapeutic effectiveness 
is limited because of their narrow therapeutic index and the 
onset of chemoresistance. Therefore, many efforts are currently 
being directed at finding new therapeutic options that may 
overcome these problems. 
Our present study was aimed at further elucidating the mo-
lecular mechanisms underlying the anti-proliferative and can-
cer preventive effects of MIS and calcitriol in order to develop 
strategies to improve OCa treatment. The results suggested 
that calcitriol enhanced the antitumor activity of MIS in OCa 
cells by down-regulating the expression of Bcl-2 and up-regu-
lating the expression of BAX, caspase-3, and caspase-9 through 
the ERK signaling pathways. 
Initial in vitro studies using human OCa cell lines or tissues 
and several follow-up studies have revealed that MIS inhibits 
the growth of human cancer cells including breast, cervical, en-
dometrial, prostate cancer, and ocular melanoma.6,8,9,15-17 In ad-
dition, a recent study indicates that MIS also plays a role in cell 
cycle arrest and apoptosis of endometriosis.18
The prophylactic and therapeutic activities of Vit D against 
the most common types of cancer have been extensively inves-
tigated both in vitro and in vivo.19-21 The most striking results 
have been obtained from studies on breast cancer, prostate 
cancer, and colorectal cancer.19,22 Experimental observations 
suggest that the chemopreventive effects of Vit D are due main-
ly to its ability to modulate important biological functions such 
as cell proliferation, cell differentiation, growth factor gene ex-
pression, signal transduction, and apoptosis.23,24 Interestingly, 
recent studies have shown that calcitriol may also affect OCa 
cell proliferation by decreasing human telomerase reverse tran-
scriptase mRNA through a small non-coding RNA.25
Vit D and TGF-β have similar effects on cell growth and dif-
ferentiation. Experimental stress studies indicate that Vit D may 
increase the expression levels of TGF-β and its receptors or 
TGF-β secretion in certain cell types.26-28 The Feldman research 
group has demonstrated that MIS, a TGF-β family member, 
constitutes a novel target gene regulated by calcitriol in pros-
tate cells.14 Exposing prostate cancer cells to calcitriol for 24 h 
resulted in a considerable increase in the expression of MIS 
mRNA. In addition, HeLa cells transfected with an MIS pro-
moter-luciferase construct and a Vit D receptor expression 
vector demonstrated a significant (two- to four-fold) induction 
of MIS promoter-luciferase following treatment with calcitriol, 
suggesting that the MIS promoter is responsive to calcitriol.13,14
Determining the utility of MIS as an anticancer drug would 
most likely involve administering MIS to patients as an adju-
vant in combination with other drugs. Therefore, elucidating 
the anti-proliferation and apoptosis signaling mechanisms 
downstream of MIS is necessary before combining MIS with 
commonly used cytotoxic drugs. Moreover, it is important to 
test for synergy or additivity between MIS and other drugs to 
ensure that they do not counteract with each other. Since little 
is known as for the signaling pathways by which MIS mediates 
proliferation inhibition and apoptosis in OCa cell lines, we in-
vestigated several potential molecular mechanisms using 
chemical inhibitors of the ERK, p38 MAPK, PI3K, and JNK 
signaling pathways. Our results demonstrated that MIS is not 
dependent on the p38 MAPK, PI3K, or JNK pathways, but that 
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the ERK pathway is activated by MIS. Consistent with our 
findings, Renlund, et al.29 reported that MIS does not activate 
the JNK pathway. In addition, they identified the JNK inhibi-
tor, SP600125, as an activator of the MIS signal transduction 
pathway.
Numerous case studies have demonstrated that serum MIS 
levels can be increased >1000-fold above the normal range 
without any significant adverse reactions; therefore, the thera-
peutic administration of MIS to cancer patients may be well 
tolerated.10 However, purified recombinant MIS is difficult 
and expensive to obtain, and the clinical use of calcitriol is lim-
ited, because of the adverse effects of hypercalcemia. Thus, sev-
eral important issues remain to be resolved prior to clinical use, 
including indication, appropriate doses, blood concentration, 
adverse effects, resistance, drug interactions, and effectiveness 
in vivo.
Despite these issues, our findings indicate that treatment 
with MIS in combination with calcitriol may be an effective 
clinical strategy for treating ovarian cancer, since combination 
of the two agents enhances the anti-proliferative and apoptot-
ic effects of each agent alone. These results, coupled with the 
need for a decrease in the toxic side effects of currently em-
ployed therapeutic agents, provide a strong rationale for test-
ing the therapeutic potential of MIS, alone or in combination 
with calcitriol, in the treatment of OCa. Future studies should 
address the exact biological functions of MIS and of the extent 
of the MIS-stimulated anti-proliferative and apoptotic activi-
ties of calcitriol. 
REFERENCES
1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Can-
cer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Berkenblit A, Cannistra SA. Advances in the management of epi-
thelial ovarian cancer. J Reprod Med 2005;50:426-38.
3. Salom E, Almeida Z, Mirhashemi R. Management of recurrent 
ovarian cancer: evidence-based decisions. Curr Opin Oncol 2002; 
14:519-27.
4. MacLaughlin DT, Teixeira J, Donahoe PK. Perspective: reproduc-
tive tract development--new discoveries and future directions. 
Endocrinology 2001;142:2167-72.
5. Coughlin JP, Donahoe PK, Budzik GP, MacLaughlin DT. Müllerian 
inhibiting substance blocks autophosphorylation of the EGF re-
ceptor by inhibiting tyrosine kinase. Mol Cell Endocrinol 1987; 
49:75-86.
6. Gupta V, Carey JL, Kawakubo H, Muzikansky A, Green JE, Dona-
hoe PK, et al. Mullerian inhibiting substance suppresses tumor 
growth in the C3(1)T antigen transgenic mouse mammary carci-
noma model. Proc Natl Acad Sci U S A 2005;102:3219-24.
7. Segev DL, Ha TU, Tran TT, Kenneally M, Harkin P, Jung M, et al. 
Mullerian inhibiting substance inhibits breast cancer cell growth 
through an NFkappa B-mediated pathway. J Biol Chem 2000;275: 
28371-9.
8. Renaud EJ, MacLaughlin DT, Oliva E, Rueda BR, Donahoe PK. 
Endometrial cancer is a receptor-mediated target for Mullerian 
Inhibiting Substance. Proc Natl Acad Sci U S A 2005;102:111-6. 
9. Barbie TU, Barbie DA, MacLaughlin DT, Maheswaran S, Donahoe 
PK. Mullerian Inhibiting Substance inhibits cervical cancer cell 
growth via a pathway involving p130 and p107. Proc Natl Acad Sci 
U S A 2003;100:15601-6.
10. MacLaughlin DT, Donahoe PK. Müllerian inhibiting substance/
anti-Müllerian hormone: a potential therapeutic agent for human 
ovarian and other cancers. Future Oncol 2010;6:391-405.
11. Ponsonby AL, Lucas RM, Lewis S, Halliday J. Vitamin D status 
during pregnancy and aspects of offspring health. Nutrients 2010; 
2:389-407.
12. Giammanco M, Di Majo D, La Guardia M, Aiello S, Crescimannno 
M, Flandina C, et al. Vitamin D in cancer chemoprevention. Pharm 
Biol 2015;53:1399-434.
13. Malloy PJ, Peng L, Wang J, Feldman D. Interaction of the vitamin 
D receptor with a vitamin D response element in the Mullerian-
inhibiting substance (MIS) promoter: regulation of MIS expres-
sion by calcitriol in prostate cancer cells. Endocrinology 2009;150: 
1580-7.
14. Krishnan AV, Moreno J, Nonn L, Malloy P, Swami S, Peng L, et al. 
Novel pathways that contribute to the anti-proliferative and che-
mopreventive activities of calcitriol in prostate cancer. J Steroid 
Biochem Mol Biol 2007;103:694-702.
15. Hoshiya Y, Gupta V, Segev DL, Hoshiya M, Carey JL, Sasur LM, et al. 
Mullerian Inhibiting Substance induces NFkB signaling in breast 
and prostate cancer cells. Mol Cell Endocrinol 2003;211:43-9.
16. Parry RL, Chin TW, Epstein J, Hudson PL, Powell DM, Donahoe 
PK. Recombinant human mullerian inhibiting substance inhibits 
human ocular melanoma cell lines in vitro and in vivo. Cancer Res 
1992;52:1182-6.
17. Kim HS, Sung YJ, Paik S. Cancer Cell Line Panels Empower Ge-
nomics-Based Discovery of Precision Cancer Medicine. Yonsei 
Med J 2015;56:1186-98.
18. Namkung J, Song JY, Jo HH, Kim MR, Lew YO, Donahoe PK, et al. 
Mullerian inhibiting substance induces apoptosis of human en-
dometrial stromal cells in endometriosis. J Clin Endocrinol Metab 
2012;97:3224-30.
19. Leyssens C, Verlinden L, Verstuyf A. Antineoplastic effects of 
1,25(OH)2D3 and its analogs in breast, prostate and colorectal 
cancer. Endocr Relat Cancer 2013;20:R31-47.
20. Pereira F, Larriba MJ, Muñoz A. Vitamin D and colon cancer. En-
docr Relat Cancer 2012;19:R51-71.
21. Swami S, Krishnan AV, Feldman D. Vitamin D metabolism and 
action in the prostate: implications for health and disease. Mol 
Cell Endocrinol 2011;347:61-9.
22. Krishnan AV, Feldman D. Molecular pathways mediating the anti-
inflammatory effects of calcitriol: implications for prostate cancer 
chemoprevention and treatment. Endocr Relat Cancer 2010;17: 
R19-38.
23. Gocek E, Studzinski GP. Vitamin D and differentiation in cancer. 
Crit Rev Clin Lab Sci 2009;46:190-209.
24. Haussler MR, Whitfield GK, Kaneko I, Haussler CA, Hsieh D, 
Hsieh JC, et al. Molecular mechanisms of vitamin D action. Calcif 
Tissue Int 2013;92:77-98.
25. Kasiappan R, Shen Z, Tse AK, Jinwal U, Tang J, Lungchukiet P, et 
al. 1,25-Dihydroxyvitamin D3 suppresses telomerase expression 
and human cancer growth through microRNA-498. J Biol Chem 
2012;287:41297-309.
26. Daniel C, Schroder O, Zahn N, Gaschott T, Steinhilber D, Stein 
JM. The TGFbeta/Smad 3-signaling pathway is involved in butyr-
ate-mediated vitamin D receptor (VDR)-expression. J Cell Bio-
chem 2007;102:1420-31.
27. Tu H, Flanders WD, Ahearn TU, Daniel CR, Gonzalez-Feliciano AG, 
Long Q, et al. Effects of calcium and vitamin D3 on transforming 
growth factors in rectal mucosa of sporadic colorectal adenoma pa-
http://dx.doi.org/10.3349/ymj.2016.57.1.3340
Effect of MIS and Calcitriol on Ovarian Cancer
tients: a randomized controlled trial. Mol Carcinog 2015;54:270-80.
28. Bizzarri M, Cucina A, Valente MG, Tagliaferri F, Borrelli V, Stipa F, 
et al. Melatonin and vitamin D3 increase TGF-beta1 release and 
induce growth inhibition in breast cancer cell cultures. J Surg Res 
2003;110:332-7.
29. Renlund N, Pieretti-Vanmarcke R, O’Neill FH, Zhang L, Donahoe 
PK, Teixeira J. c-Jun N-terminal kinase inhibitor II (SP600125) ac-
tivates Mullerian inhibiting substance type II receptor-mediated 
signal transduction. Endocrinology 2008;149:108-15.
